Antiphospholipid syndrome (APS) is an autoimmune condition characterized by thrombosis and pregnancy morbidity. 1 Thrombotic APS variably involves arterial, venous, and microvascular circulations.
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The pathophysiology of thrombotic APS is thought to involve the generation of autoantibodies that bind to the major B-cell epitope on domain I of the β 2 -glycoprotein. This binding and subsequent thrombus formation occurs through intermediary processes that likely include oxidative stress, 2 complement activation, 3 and neutrophils 4 invoking a "2-hit" process of initial endothelial disruption followed by thrombus formation. 5 Laboratory diagnostic criteria for APS include the presence of any one of the qualifying antibody isotypes (anticardiolipin IgG or IgM, anti-β 2 -glycoprotein-1 IgG or IgM) and titers, or the presence of a lupus anticoagulant (LA) initially and again at least 12 weeks later.
Anticoagulant therapy is the mainstay of treatment for thrombotic APS, and due to the high risk for thrombosis progression and recurrence, indefinite anticoagulation is often considered. 6 Even with use of vitamin K antagonists (VKA) the annual rate of recurrent thrombosis is at least 1.5% 7 and potentially as high as 30% over 5 years. 8, 9 Direct oral anticoagulants (DOACs) offer a simpler therapeutic regimen with greater convenience than VKA therapy, and are approved for the treatment and secondary prevention of venous thromboembolism (VTE). 10, 11 There remains great interest to offer APS patients an alternative to VKA therapy, provided that this is safe and effective. The limited available evidence from prospective and retrospective studies was presented in a systematic review 12 and a patient-level meta-analysis. 13 Concerningly, these analyses reported recurrent thrombosis rates around 15% among APS patients treated with DOACs with as high as a 4-fold increased risk for recurrence among those patients that have all 3 APS lab tests positive-"triple positivity." 13 These publications have significant limitations (eg, meta-analyses include multiple case reports with an n = 1 that potentially amplify selection and publication biases, patients that experienced thrombosis on other anticoagulants prior to receiving a DOAC were included, and studies were retrospective). randomized to warfarin after 569 days' follow-up. No VTEs were observed. Most recently in a randomized controlled trial, Ordi-Ros and colleagues 16 failed to demonstrate that rivaroxaban 20 mg daily was noninferior to VKA (target INR, 2.5; or target INR, 3.5 in patients with a history of recurrent thrombosis) among 190 adults with VTE or arterial thrombotic APS with a comparative risk for recurrent thrombosis of 1.83 (exceeding the predetermined noninferiority margin of 1.4) and a relative risk for stroke of 19 (95% confidence interval [CI], 1.12-321.9). A Canadian study followed 81 patients with APS receiving rivaroxaban for about a year, but the results are not yet known (Clini calTr ials.gov Identifier: NCT02116036); another study with a different DOAC (apixaban) is ongoing. 17, 18 For several reasons, more evidence is needed regarding the effi- About 10% of patients with unprovoked VTE will be diagnosed with APS if all patients are tested. 23 Therefore, 10 patients would need to be evaluated to potentially change the management of 1 patient. Further, it is uncertain whether patients with APS discovered in this manner are similar to patients with clinically detected APS who were enrolled in prior clinical trials comparing DOACs with VKA.
If testing to determine APS status prior to choosing treatment among patients with unprovoked VTE is elected, then perhaps the epidemiology of APS can inform who should be tested. Clinical manifestations of APS generally affect young and middle-aged adults, with 85% of patients between 15 and 50 years of age. 24 Also, APS is more common in women than men, with a male-to-female ratio that varies and ranging from 1:3.5 for primary APS to 1:7 for secondary APS associated with systemic lupus erythematosus. 23 The US Food and Drug Administration recently updated their guidance regarding APS for rivaroxaban(CITE), 28 and the US package insert for both rivaroxaban and apixaban include the EMA language noted above. 10, 11 In the absence of definitive published level I evidence, the EMA guidance statement may be perceived as premature and may discourage ongoing research (Clini calTr ials.
gov Identifier: NCT03684564) in this arena. We therefore suggest that societies that provide leadership on this topic, including the International Society of Thrombosis and Haemostasis, 25 APS Action, 26 and Anticoagulation Forum, 27 consider guidance statements for clinicians on whether to evaluate patients with unprovoked VTE for antiphospholipid antibodies. We call for further studies to create a sufficient body of evidence to inform the pragmatic anticoagulant treatment of patients with APS.
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